| Literature DB >> 35273837 |
Ashok Kumar Sahoo1,2, Narendranath Swain1, Arun Kumar Mohanty1, Sibabrata Kar3, Nagendra Kumar Rajsamant1, Santosh Kumar Behera1.
Abstract
Introduction Diabetes secondary to pancreatic diseases is commonly referred to as pancreatogenic diabetes or type 3c diabetes mellitus. This study was conducted to determine the status of diabetes mellitus after Frey's procedure and lateral pancreaticojejunostomy (LPJ) in diabetic and nondiabetic patients with chronic calcific pancreatitis (CCP) and to discuss the clinicopathological course as well as diabetes in CCP. Materials and methods This study was designed as a retrospective observational study consisting of 27 patients with CCP who were surgically treated either with the pancreatic head coring Frey's procedure or with LPJ. Surgeries were performed in a tertiary care hospital of Eastern India by a team of surgeons following the same surgical principle. The diagnosis of CCP was made by clinical and radiological evaluations. Visual Analog Scale (VAS) scoring was used perioperatively to assess pain. Postoperatively, all the patients were monitored clinically; pain scoring and relevant investigations were done depending upon subjective and objective indications. Special attention was paid to diabetic patients through frequent follow-ups and tight glycemic control. All 27 patients were followed up with at least two outpatient follow-ups. Results The trends in fasting blood sugar values in the LPJ group showed a small spike in the early postoperative period (two weeks) with a p-value of >0.05, and later on, it improved over 18 months of follow-up, reaching below the preoperative values (mean 109.38). On the contrary, the fasting blood glucose levels in Frey's procedure revealed a significant spike in the early postoperative period (two weeks) with a mean sugar value of 148 mg/dl and a p-value of 0.01. The levels stayed well above the preoperative values over 18 months of follow-up. The trends in HbA1c showed marginal improvement in the LPJ group in a six-month follow-up period (p-value 0.008) from the preoperative levels. In Frey's procedure group, postoperative HbA1c levels at three months revealed an increase, which can be attributed to the minor but significant loss of pancreatic tissue from the head, which continued to be on the higher side at the six-month follow-up. Trends in mean insulin dosage showed a significant spike in the early postoperative period (two weeks) both in the LPJ (p-value 0.01) and Frey's procedure group (0.01); however, in the LPJ group, the insulin dose showed a reduction over the 18-month follow-up, reaching below the mean preoperative insulin dose. While in the Frey's procedure group, the postoperative insulin dose remained higher throughout the 18-month follow-up period (p-value <0.05). Conclusions LPJ has got a little effect on the diabetic status of nondiabetic patients. Frey's procedure leads to marginal deterioration of the diabetic status and increases in insulin dosage in both diabetic and nondiabetic patients.Entities:
Keywords: alcohol; clinicopathological diagnosis; drainage procedure; follow-up; insulin
Year: 2022 PMID: 35273837 PMCID: PMC8901132 DOI: 10.7759/cureus.21855
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Demographic Characteristics
LPJ: lateral pancreatojejunostomy
| Qualitative Variables | LPJ Group (14)(%) | Frey’s Group (13)(%) | P-value | |
| Sex | Male | 9(64.3) | 8(61.5) | 0.883 |
| Female | 5(35.7) | 5(38.5) | ||
| Socioeconomic status | Low | 11(78.6) | 8(61.5) | 0.333 |
| Medium | 3(21.4) | 5(38.5) | ||
| High | 0 | 0 | ||
| Alcoholism | Yes | 7(50) | 4(30.8) | 0.310 |
| No | 7(50) | 9(69.2) | ||
| Smoking | Yes | 4(28.6) | 6(46.2) | 0.345 |
| No | 10(71.4) | 7(53.8) | ||
| Hyperlipidemia | Yes | 4(28.6) | 8(61.5) | 0.085 |
| No | 10(71.4) | 5(38.5) | ||
| Recurrent acute pancreatitis | Yes | 10(71.4) | 10(76.9) | 0.745 |
| No | 4(28.6) | 3(23.1) | ||
| Cambridge score | Mild | 0 | 0 | 0.580 |
| Moderate | 11(78.6) | 9(69.2) | ||
| Severe | 3(21.4) | 4(30.8) | ||
| Preoperative Oral Hypoglycemic Agents use | Yes | 1(7.1) | 1(7.7) | 0.957 |
| No | 13(92.9) | 12(92.3) | ||
| Postoperative Oral Hypoglycemic Agents dosage change | Yes | 1(7.1) | 2(15.4) | 0.496 |
| No | 13(92.9) | 11(84.6) |
Baseline Characteristics
FBS: fasting blood sugar; LPJ: lateral pancreatojejunostomy
| Quantitative Variables | LPJ Group | Frey’s Group | T-Value | P-value | |
| Weight | Mean | 58.5 | 60.77 | 0.577 | 0.569 |
| SD | 9.558 | 10.872 | |||
| BMI | Mean | 22.60 | 23.2 | 0.794 | 0.434 |
| SD | 3.79 | 3.25 | |||
| Serum amylase | Mean | 40.43 | 61.23 | 1.728 | 0.096 |
| SD | 27.046 | 35.235 | |||
| Serum lipase | Mean | 40.14 | 59.46 | 1.322 | 0.198 |
| SD | 41.757 | 33.293 | |||
| Preop FBS | Mean | 125.93 | 122.46 | 0.188 | 0.853 |
| SD | 51.53 | 43.714 | |||
| Preop HbA1c | Mean | 6.829 | 6.623 | 0.445 | 0.660 |
| SD | 1.1384 | 1.2597 | |||
| Preop insulin | Mean | 15.79 | 10 | 1.084 | 0.288 |
| SD | 15.423 | 11.916 | |||
| FBS 2 weeks | Mean | 131.14 | 148 | 1.166 | 0.255 |
| SD | 37.554 | 11.916 | |||
| FBS 3 months | Mean | 123.14 | 135.62 | 1.248 | 0.224 |
| SD | 24.507 | 27.421 | |||
| FBS 6 months | Mean | 114.23 | 134.77 | 1.892 | 0.071 |
| SD | 22.5 | 32.037 | |||
| FBS 12 months | Mean | 110.77 | 132.38 | 2.318 | 0.029 |
| SD | 25.2 | 22.262 | |||
| FBS 18 months | Mean | 109.38 | 126.31 | 1.726 | 0.97 |
| SD | 25.695 | 24.274 | |||
| HbA1c 3 months | Mean | 6.871 | 6.908 | 0.100 | 0.921 |
| SD | 0.8905 | 0.9987 | |||
| HbA1c 6 months | Mean | 6.631 | 6.946 | 0.978 | 0.338 |
| SD | 0.7941 | 0.8491 | |||
| Postop insulin 3 months | Mean | 20.371 | 16 | 0.799 | 0.432 |
| SD | 15.6520 | 12.4633 | |||
| Postop insulin 6 months | Mean | 16 | 16.77 | 0.123 | 0.903 |
| SD | 17.504 | 13.154 | |||
| Postop insulin 1 year | Mean | 17.23 | 15.69 | 0.266 | 0.792 |
| SD | 16.942 | 12.106 | |||
| Postop insulin 18 months | Mean | 15.68 | 15.08 | 0.004 | 1.00 |
| SD | 16.424 | 10.943 |
Paired T-Test of Mean Pre- and Postoperative FBS for the LPJ Group
FBS: fasting blood sugar; LPJ: lateral pancreatojejunostomy; Preop: preoperative; Postop: postoperative
| T-Value | P-Value | |||
| Pair 1 | Preop FBS | 125.93 | 0.845 | 0.413 |
| Postop FBS 2 weeks | 131.14 | |||
| Pair 2 | Preop FBS | 125.93 | 0.287 | 0.779 |
| Postop FBS 3 months | 123.14 | |||
| Pair 3 | Preop FBS | 129.15 | 1.370 | 0.196 |
| Postop FBS 6 months | 114.23 | |||
| Pair 4 | Preop FBS | 129.15 | 1.537 | 0.150 |
| Postop FBS 12 months | 110.77 | |||
| Pair 5 | Preop FBS | 129.15 | 1.689 | 0.117 |
| Postop FBS 18 months | 109.38 |
Paired T-Test of Mean Pre- and Postoperative FBS for Frey’s Procedure Group
FBS: fasting blood sugar; Preop: preoperative; Postop: postoperative
| T-Value | P-Value | |||
| Pair 1 | Preop FBS | 122.46 | 4.219 | 0.01 |
| Postop FBS 2 weeks | 148 | |||
| Pair 2 | Preop FBS | 122.46 | 1.689 | 0.117 |
| Postop FBS 3 months | 135.62 | |||
| Pair 3 | Preop FBS | 122.46 | 1.370 | 0.196 |
| Postop FBS 6 months | 134.77 | |||
| Pair 4 | Preop FBS | 122.46 | 1.097 | 0.294 |
| Postop FBS 12 months | 132.38 | |||
| Pair 5 | Preop FBS | 122.46 | 0.393 | 0.698 |
| Postop FBS 18 months | 126.31 |
Paired T-Test for Pre- and Postoperative HbA1c for the LPJ Group
LPJ: lateral pancreatojejunostomy; Preop: preoperative; Postop: postoperative
| HbA1c | T-Value | P-Value | ||
| Pair 1 | Preop HbA1c | 6.829 | 0.346 | 0.735 |
| Postop HbA1c 3 months | 6.871 | |||
| Pair 2 | Preop HbA1c | 7.008 | 3.172 | 0.008 |
| Postop HbA1c 6 months | 6.631 |
Paired T-Test for Pre- and Postoperative HbA1c for the Frey’s Procedure Group
Preop: preoperative; Postop: postoperative
| HbA1c level | T-Value | P-Value | ||
| Pair 1 | Preop HbA1c | 6.623 | 2.047 | 0.063 |
| Postop HbA1c 3 months | 6.908 | |||
| Pair 2 | Preop HbA1c | 6.623 | 1.376 | 0.194 |
| Postop HbA1c 6 months | 6.946 |
Paired T-Test for Pre- and Postoperative Insulin Dose in the LPJ Group
LPJ: lateral pancreatojejunostomy; Preop: preoperative; Postop: postoperative
| T-Value | P-Value | |||
| Pair 1 | Preop insulin dose | 15.79 | 4.196 | 0.01 |
| Postop insulin dose 3 months | 20.371 | |||
| Pair 2 | Preop insulin dose | 16.46* | 1.720 | 0.111 |
| Postop insulin dose 6 months | 19.23 | |||
| Pair 3 | Preop insulin dose | 16.46* | 2.941 | 0.660 |
| Postop insulin dose 12 months | 17.23 | |||
| Pair 4 | Preop insulin dose | 16.46* | 5.122 | 0.435 |
| Postop insulin dose 18 months | 15.08 |
Paired T-Test for Pre- and Postoperative Insulin Dose in the Frey’s Procedure Group
LPJ: lateral pancreatojejunostomy; Preop: preoperative; Postop: postoperative
| T-Value | P-Value | |||
| Pair 1 | Preop insulin dose | 10 | 4.544 | 0.01 |
| Postop insulin dose 3 months | 16 | |||
| Pair 2 | Preop insulin | 10 | 4.879 | 0.001 |
| Postop insulin dose 6 months | 16.77 | |||
| Pair 3 | Preop insulin dose | 10 | 4.086 | 0.002 |
| Postop insulin dose 12 months | 15.69 | |||
| Pair 4 | Preop insulin dose | 10 | 3.518 | 0.004 |
| Postop insulin dose 18 months | 15.08 |